JP2005523312A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005523312A5 JP2005523312A5 JP2003585656A JP2003585656A JP2005523312A5 JP 2005523312 A5 JP2005523312 A5 JP 2005523312A5 JP 2003585656 A JP2003585656 A JP 2003585656A JP 2003585656 A JP2003585656 A JP 2003585656A JP 2005523312 A5 JP2005523312 A5 JP 2005523312A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- hydrogen
- compound
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 carboxyamido Chemical group 0.000 claims 168
- 150000001875 compounds Chemical class 0.000 claims 65
- 229910052739 hydrogen Inorganic materials 0.000 claims 56
- 239000001257 hydrogen Substances 0.000 claims 56
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 30
- 150000002431 hydrogen Chemical class 0.000 claims 25
- 125000003107 substituted aryl group Chemical group 0.000 claims 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 21
- 125000001072 heteroaryl group Chemical group 0.000 claims 17
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 125000000547 substituted alkyl group Chemical group 0.000 claims 13
- 125000005843 halogen group Chemical group 0.000 claims 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 12
- 125000003710 aryl alkyl group Chemical group 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 10
- 239000012453 solvate Substances 0.000 claims 10
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 9
- 125000003944 tolyl group Chemical group 0.000 claims 8
- 125000001624 naphthyl group Chemical group 0.000 claims 7
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 7
- 125000002946 cyanobenzyl group Chemical group 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 125000005059 halophenyl group Chemical group 0.000 claims 5
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000006277 halobenzyl group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000002883 imidazolyl group Chemical group 0.000 claims 4
- 125000003282 alkyl amino group Chemical group 0.000 claims 3
- 125000004802 cyanophenyl group Chemical group 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 102000010638 Kinesin Human genes 0.000 claims 2
- 108010063296 Kinesin Proteins 0.000 claims 2
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000004803 chlorobenzyl group Chemical group 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- 125000006286 dichlorobenzyl group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000002636 imidazolinyl group Chemical group 0.000 claims 2
- 125000006178 methyl benzyl group Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical class 0.000 claims 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims 1
- 229940122803 Vinca alkaloid Drugs 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000000499 benzofuranyl group Chemical class O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004799 bromophenyl group Chemical group 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 125000000068 chlorophenyl group Chemical group 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 125000005433 dihydrobenzodioxinyl group Chemical group O1C(COC2=C1C=CC=C2)* 0.000 claims 1
- 125000006202 diisopropylaminoethyl group Chemical group [H]C([H])([H])C([H])(N(C([H])([H])C([H])([H])*)C([H])(C([H])([H])[H])C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000005805 dimethoxy phenyl group Chemical group 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000006289 hydroxybenzyl group Chemical group 0.000 claims 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 150000002460 imidazoles Chemical class 0.000 claims 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 150000003891 oxalate salts Chemical class 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000006513 pyridinyl methyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37345402P | 2002-04-17 | 2002-04-17 | |
| US41068202P | 2002-09-13 | 2002-09-13 | |
| PCT/US2003/011432 WO2003088903A2 (en) | 2002-04-17 | 2003-04-11 | Compounds, compositions, and methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005523312A JP2005523312A (ja) | 2005-08-04 |
| JP2005523312A5 true JP2005523312A5 (https=) | 2006-05-18 |
| JP4664597B2 JP4664597B2 (ja) | 2011-04-06 |
Family
ID=29254526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003585656A Expired - Fee Related JP4664597B2 (ja) | 2002-04-17 | 2003-04-11 | 化合物、組成物および方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (7) | US6924376B2 (https=) |
| EP (1) | EP1511734B1 (https=) |
| JP (1) | JP4664597B2 (https=) |
| KR (1) | KR101052816B1 (https=) |
| CN (1) | CN100381437C (https=) |
| AR (1) | AR039419A1 (https=) |
| AT (1) | ATE471931T1 (https=) |
| AU (1) | AU2003234733B2 (https=) |
| BR (1) | BR0309278A (https=) |
| CA (1) | CA2482041C (https=) |
| DE (1) | DE60333094D1 (https=) |
| DK (1) | DK1511734T3 (https=) |
| IL (2) | IL164581A (https=) |
| MX (1) | MXPA04010240A (https=) |
| MY (1) | MY140169A (https=) |
| NO (1) | NO330433B1 (https=) |
| NZ (1) | NZ536190A (https=) |
| PL (1) | PL211300B1 (https=) |
| RU (1) | RU2308454C9 (https=) |
| TW (1) | TWI282337B (https=) |
| WO (1) | WO2003088903A2 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ536190A (en) * | 2002-04-17 | 2007-08-31 | Cytokinetics Inc | Compounds for treating cellular proliferative diseases by modulating the activity of the mitotic kinesin KSP |
| DE60326248D1 (de) * | 2002-07-17 | 2009-04-02 | Cytokinetics Inc | Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen |
| EP1554265A4 (en) * | 2002-09-13 | 2008-05-07 | Cytokinetics Inc | COMPOSITIONS, COMPOSITIONS AND M THODES |
| AR050920A1 (es) * | 2003-03-07 | 2006-12-06 | Astrazeneca Ab | Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos |
| NZ542227A (en) * | 2003-03-07 | 2008-12-24 | Astrazeneca Ab | Novel fused heterocycles and uses thereof |
| US20050165089A1 (en) * | 2003-10-06 | 2005-07-28 | Gustave Bergnes | Compounds, compositions and methods |
| WO2005087747A1 (en) * | 2004-03-08 | 2005-09-22 | Wyeth | Ion channel modulators |
| US20070191448A1 (en) * | 2004-03-08 | 2007-08-16 | Robert Zelle | Ion channel modulators |
| ES2311992T3 (es) * | 2004-05-21 | 2009-02-16 | Novartis Vaccines And Diagnostics, Inc. | Derivados de quinolina sustituida com,o inhibidores de cinesina mitotica. |
| WO2006008523A1 (en) * | 2004-07-22 | 2006-01-26 | Astrazeneca Ab | Fused pyrimidones usefuel in the treatment and the prevention of cancer |
| KR20070046175A (ko) * | 2004-08-18 | 2007-05-02 | 아스트라제네카 아베 | 선택된 융합 복소환 및 이의 용도 |
| US20060041128A1 (en) * | 2004-08-18 | 2006-02-23 | Astrazeneca Ab | Selected fused heterocyclics and uses thereof |
| EP1781674A1 (en) | 2004-08-18 | 2007-05-09 | AstraZeneca AB | Enantiomers of selected fused pyrimidones and uses in the treatment and prevention of cancer |
| WO2006060737A2 (en) * | 2004-12-03 | 2006-06-08 | Takeda San Diego, Inc. | Mitotic kinesin inhibitors |
| US20090221488A1 (en) * | 2005-12-08 | 2009-09-03 | Wood Kenneth W | Certain Compositions and Methods of Treatment |
| WO2007106818A1 (en) * | 2006-03-13 | 2007-09-20 | University Of Florida Research Foundation, Inc. | Synthesis of pentafluorosulfanyl (sf5)-substituted heterocycles and alkynes |
| WO2007134183A2 (en) * | 2006-05-13 | 2007-11-22 | Advanced Technology Materials, Inc. | Chemical reagent delivery system utilizing ionic liquid storage medium |
| WO2008086122A2 (en) | 2007-01-05 | 2008-07-17 | Novartis Ag | Imidazole derivatives as kinesin spindle protein inhibitors (eg-5) |
| NZ599830A (en) | 2009-11-05 | 2014-08-29 | Rhizen Pharmaceuticals Sa | Novel kinase modulators |
| KR102263079B1 (ko) * | 2009-11-05 | 2021-06-10 | 리젠 파마슈티컬스 소시에떼 아노님 | 신규한 벤조피란 키나제 조절제 |
| WO2012066330A1 (en) | 2010-11-17 | 2012-05-24 | Heptares Therapeutics Limited | Compounds useful as a2a receptor inhibitors |
| PH12013502240B1 (en) * | 2011-05-04 | 2018-06-27 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of protein kinase |
| RS56494B1 (sr) * | 2012-07-04 | 2018-01-31 | Rhizen Pharmaceuticals S A | Selektivni inhibitori pi3k delta |
| KR20150095779A (ko) * | 2012-12-13 | 2015-08-21 | 글락소스미스클라인 엘엘씨 | 제스트 인핸서 상동체 2 억제제 |
| AU2014288839B2 (en) | 2013-07-10 | 2017-02-02 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of Zeste Homolog 2 inhibitors |
| EP3325462A4 (en) * | 2015-07-23 | 2019-06-19 | Pharmakea, Inc. | INHIBITORS OF LYSYL OXIDASE-LIKE 2 AND USES OF SAID INHIBITORS |
| CA3013917A1 (en) | 2016-02-09 | 2017-08-17 | Pharmakea, Inc. | Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof |
| CN111991389B (zh) * | 2020-09-17 | 2021-11-23 | 陕西科技大学 | Sb-743921用于制备抗真菌药物的用途 |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US169159A (en) * | 1875-10-26 | Improvement in corsets | ||
| US116400A (en) * | 1871-06-27 | Improvement in heels for boots and shoes | ||
| US55054A (en) * | 1866-05-29 | Improvement in lamp-chimneys | ||
| GB728767A (en) * | 1951-10-12 | 1955-04-27 | Wander Ag Dr A | 2-substituted chromone compounds, and a method of making same |
| NL84159C (https=) | 1952-06-30 | |||
| EP0020018B1 (en) | 1979-05-19 | 1983-06-01 | Beecham Group Plc | Chroman derivatives, processes for their preparation and pharmaceutical compositions containing them |
| DE3177130D1 (de) | 1980-08-30 | 1990-01-11 | Hoechst Ag | Aminosaeurederivate, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung. |
| US4434295A (en) | 1982-05-17 | 1984-02-28 | The Upjohn Company | Anti-atherosclerotic 6,7-dihydro-7,7-disubstituted-khellin analogs |
| US4434296A (en) | 1982-05-17 | 1984-02-28 | The Upjohn Company | Process for preparing intermediates for antiatherosclerotic compounds |
| US4459420A (en) | 1982-05-17 | 1984-07-10 | The Upjohn Company | Pyrogallol synthesis of anti-atherogenic furochromones |
| US4482558A (en) | 1982-06-18 | 1984-11-13 | Pfizer Inc. | Antifungal amide and urea derivatives of (3-amino-2-aryl-2-hydroxyprop-1-yl)-1H-1,2,4-triazoles |
| JPS62201882A (ja) * | 1985-11-18 | 1987-09-05 | Yamanouchi Pharmaceut Co Ltd | イソフラボン誘導体 |
| IN164232B (https=) | 1986-04-11 | 1989-02-04 | Hoechst India | |
| IL85554A0 (en) | 1987-03-02 | 1988-08-31 | Takeda Chemical Industries Ltd | Chromone derivatives |
| JPH0753725B2 (ja) | 1987-10-08 | 1995-06-07 | 富山化学工業株式会社 | ４ｈ―１―ベンゾピラン―４―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤 |
| MX13485A (es) * | 1987-10-19 | 1993-05-01 | Pfizer | Procedimiento para obtener tetralinas, cromados y compuestos relacionados, sustituidos |
| USH1427H (en) | 1988-04-06 | 1995-04-04 | Briet; Phillipe | Substituted flavonoid compounds, their salts, their manufacture and their use in combination with interleukin-2 |
| IL89840A (en) | 1988-04-06 | 1996-10-31 | Lipha | Substituted flavonoid compounds and salts thereof their preparation and pharmaceutical composition containing them |
| US5304548A (en) | 1988-08-16 | 1994-04-19 | The Upjohn Company | Bivalent ligands effective for blocking ACAT enzyme for lowering plasma triglycerides and for elevating HDL cholesterol |
| US5180717A (en) | 1988-08-16 | 1993-01-19 | The Upjohn Company | Bivalent ligands effective for blocking ACAT enzyme for lowering plasma triglycerides and for elevating HDL cholesterol |
| US5284856A (en) | 1988-10-28 | 1994-02-08 | Hoechst Aktiengesellschaft | Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives |
| DE3836676A1 (de) | 1988-10-28 | 1990-05-03 | Hoechst Ag | Die verwendung von 4h-1-benzopyran-4-on-derivaten, neue 4h-1-benzopyran-4-on-derivate und diese enthaltende arzneimittel |
| AU634994B2 (en) * | 1988-12-21 | 1993-03-11 | Pharmacia & Upjohn Company | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones |
| US5703075A (en) | 1988-12-21 | 1997-12-30 | Pharmacia & Upjohn Company | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones |
| US4977162A (en) | 1989-07-13 | 1990-12-11 | Rorer Pharmaceutical Corporation | Quinolinyl-chromone derivatives and use for treatment of hypersensitive ailments |
| US5082849A (en) | 1989-07-13 | 1992-01-21 | Huang Fu Chich | Quinolinyl-benzopyran derivatives as antagonists of leukotriene D4 |
| US5032598A (en) | 1989-12-08 | 1991-07-16 | Merck & Co., Inc. | Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents |
| US5215989A (en) | 1989-12-08 | 1993-06-01 | Merck & Co., Inc. | Nitrogen-containing heterocyclic compounds as class III antiarrhythmic agents |
| EP0525123B1 (en) | 1990-06-20 | 1997-09-17 | PHARMACIA & UPJOHN COMPANY | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones |
| ATE161837T1 (de) | 1990-07-25 | 1998-01-15 | Teijin Ltd | Benzopyran derivat, seine darstellung und pharmazeutische zusammensetzung, welche dieses enthält |
| CA2067167A1 (en) | 1990-09-28 | 1992-03-29 | Tokuo Matuzaki | Method of producing carbonic acid diester |
| AU8506791A (en) | 1990-10-01 | 1992-04-28 | Janssen Pharmaceutica N.V. | Novel 4-piperidinylcarbonyl derivatives |
| JPH05301813A (ja) | 1991-10-15 | 1993-11-16 | Kao Corp | 皮膚外用剤 |
| EP0623608B1 (en) | 1992-01-24 | 2001-05-30 | Teijin Limited | Benzopyran derivative, production thereof, and pharmaceutical preparation containing the same as active ingredient |
| GB9203497D0 (en) * | 1992-02-19 | 1992-04-08 | Lilly Industries Ltd | Pharmaceutical compounds |
| US5605896A (en) | 1992-02-25 | 1997-02-25 | Recordati S.A., Chemical And Pharmaceutical Company | Bicyclic heterocyclic derivatives having α1 adrenergic and 5HT1A activities |
| FR2693196B1 (fr) | 1992-07-03 | 1994-12-23 | Lipha | Dérivés de benzopyranone ou de benzothiopyranone, procédé de préparation et composition pharmaceutique les contenant. |
| JP2579303Y2 (ja) * | 1992-08-14 | 1998-08-27 | 株式会社共立 | バリカン形刈払機 |
| JPH09509428A (ja) | 1994-02-23 | 1997-09-22 | カイロン コーポレイション | 薬理学的に活性な薬剤の血清半減期を増加させるための方法および組成物 |
| WO1995034547A1 (en) * | 1994-06-10 | 1995-12-21 | Smithkline Beecham Plc | C-4 amide substituted compounds and their use as therapeutic agents |
| US5607928A (en) | 1994-08-05 | 1997-03-04 | Zeneca Limited | Carbapenem derivatives containing a bicyclic ketone substituent and their use as anti-infectives |
| GB9417969D0 (en) | 1994-09-07 | 1994-10-26 | King S College London | Alkaloids and derivatives thereof |
| US5602171A (en) | 1995-06-07 | 1997-02-11 | Sugen Inc. | Methods of inhibiting phosphatase activity and treatment of disorders associated therewith using naphthopyrones and derivatives thereof |
| AU4153496A (en) | 1995-10-20 | 1997-05-07 | Flora Inc. | Transdermal delivery of alpha adrenoceptor blocking agents |
| NL1003520C2 (nl) | 1996-07-05 | 1998-01-07 | Stork Amsterdam | Sterilisatie-inrichting en werkwijze voor het steriliseren van voorwerpen. |
| US5908934A (en) | 1996-09-26 | 1999-06-01 | Bristol-Myers Squibb Company | Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs |
| JPH10273467A (ja) * | 1997-01-29 | 1998-10-13 | Snow Brand Milk Prod Co Ltd | 新規テトラロン又はベンゾピラノン誘導体及びその製造方法 |
| GB9807779D0 (en) | 1998-04-09 | 1998-06-10 | Ciba Geigy Ag | Organic compounds |
| DE19850131A1 (de) * | 1998-10-30 | 2000-05-04 | Merck Patent Gmbh | Chromenon- und Chromanonderivate |
| US6028088A (en) | 1998-10-30 | 2000-02-22 | The University Of Mississippi | Flavonoid derivatives |
| US6087385A (en) | 1998-10-30 | 2000-07-11 | University Of Mississippi | Flavonoid derivatives |
| DE19858341A1 (de) * | 1998-12-17 | 2000-06-21 | Merck Patent Gmbh | Chromanderivate |
| US6399633B1 (en) * | 1999-02-01 | 2002-06-04 | Aventis Pharmaceuticals Inc. | Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation |
| GB9911071D0 (en) | 1999-05-12 | 1999-07-14 | Darwin Discovery Ltd | Hydroxamic and carboxylic acid derivatives |
| WO2001016114A2 (en) | 1999-08-27 | 2001-03-08 | Chemocentryx, Inc. | Heterocyclic compounds and methods for modulating cxcr3 function |
| GB9920912D0 (en) | 1999-09-03 | 1999-11-10 | Indena Spa | Novel derivatives of flavones,xanthones and coumarins |
| GB9920910D0 (en) | 1999-09-03 | 1999-11-10 | Indena Spa | Novel chalcones |
| JP4994552B2 (ja) | 1999-09-16 | 2012-08-08 | キュリス，インコーポレイテッド | ヘッジホッグシグナル伝達経路のメディエーター、組成物及びそれらと関連する利用 |
| US6552016B1 (en) | 1999-10-14 | 2003-04-22 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| US6545004B1 (en) | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
| US6683192B2 (en) | 2000-03-30 | 2004-01-27 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| EP1280789A1 (en) * | 2000-05-03 | 2003-02-05 | LG Life Sciences Ltd. | Cdk inhibitors having 3-hydroxychromen-4-one structure |
| US6559145B2 (en) | 2000-07-12 | 2003-05-06 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
| DE10036003A1 (de) | 2000-07-25 | 2002-02-14 | Aventis Cropscience Gmbh | Herbizide Mittel |
| US6903121B1 (en) | 2000-08-17 | 2005-06-07 | Allergan, Inc. | Treatment of tumors with acetylenes disubstituted with a phenyl or heteroaromatic group and a substituted chromanyl, thiochromanyl or tetrahydroquinolinyl group in combination with other anti-tumor agents |
| NZ526622A (en) | 2000-12-11 | 2006-07-28 | Amgen Sf Llc | CXCR3 antagonists |
| JP2002322169A (ja) | 2001-02-21 | 2002-11-08 | Sankyo Co Ltd | クロメン誘導体 |
| BR0211513A (pt) | 2001-07-27 | 2005-08-30 | Curis Inc | Mediadores de caminhos sinalizantes de hedgehog, composições e usos relacionados ao mesmo |
| SE0103648D0 (sv) * | 2001-11-01 | 2001-11-01 | Astrazeneca Ab | Therapeutic quinolone compounds |
| JP2005511581A (ja) | 2001-11-07 | 2005-04-28 | メルク エンド カムパニー インコーポレーテッド | 有糸分裂キネシン阻害剤 |
| CA2467722A1 (en) | 2001-12-06 | 2003-06-19 | Merck & Co., Inc. | Thienopyrimidinone derivatives as mitotic kinesin inhibitors |
| CA2468156A1 (en) | 2001-12-06 | 2003-06-19 | Merck & Co., Inc. | Azolopyrimidinone compounds and their use |
| JP2005515208A (ja) | 2001-12-06 | 2005-05-26 | メルク エンド カムパニー インコーポレーテッド | 有糸分裂性キネシン阻害剤 |
| WO2003049527A2 (en) | 2001-12-06 | 2003-06-19 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| US20050107404A1 (en) | 2001-12-06 | 2005-05-19 | Fraley Mark E. | Mitotic kinesin inhibitors |
| AU2003249597B2 (en) | 2002-03-08 | 2007-06-28 | Merck Sharp & Dohme Corp. | Mitotic kinesin inhibitors |
| NZ536190A (en) * | 2002-04-17 | 2007-08-31 | Cytokinetics Inc | Compounds for treating cellular proliferative diseases by modulating the activity of the mitotic kinesin KSP |
| EP1509507A4 (en) | 2002-05-23 | 2006-09-13 | Merck & Co Inc | INHIBITORS OF MITOTIC KINESINE |
| ATE356804T1 (de) | 2002-06-14 | 2007-04-15 | Merck & Co Inc | Inhibitoren von mitotischem kinesin |
| EP1515724B1 (en) | 2002-06-14 | 2009-10-21 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| AU2003247891A1 (en) | 2002-07-08 | 2004-01-23 | Merck & Co., Inc. | Mitotic kinesin binding site |
| DE60326248D1 (de) * | 2002-07-17 | 2009-04-02 | Cytokinetics Inc | Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen |
| WO2004014388A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors |
| EP1554265A4 (en) * | 2002-09-13 | 2008-05-07 | Cytokinetics Inc | COMPOSITIONS, COMPOSITIONS AND M THODES |
| US20050165089A1 (en) * | 2003-10-06 | 2005-07-28 | Gustave Bergnes | Compounds, compositions and methods |
| WO2005040163A1 (en) | 2003-10-28 | 2005-05-06 | Dr. Reddy's Laboratories Ltd | Heterocyclic compounds that block the effects of advanced glycation end products (age) |
| JP4502322B2 (ja) | 2004-11-08 | 2010-07-14 | Ａｇｃテクノグラス株式会社 | ガラス管の曲げ加工方法およびその成形用金型 |
-
2003
- 2003-04-11 NZ NZ536190A patent/NZ536190A/en not_active IP Right Cessation
- 2003-04-11 DK DK03728389.2T patent/DK1511734T3/da active
- 2003-04-11 CN CNB038140667A patent/CN100381437C/zh not_active Expired - Fee Related
- 2003-04-11 MX MXPA04010240A patent/MXPA04010240A/es active IP Right Grant
- 2003-04-11 KR KR1020047016771A patent/KR101052816B1/ko not_active Expired - Fee Related
- 2003-04-11 WO PCT/US2003/011432 patent/WO2003088903A2/en not_active Ceased
- 2003-04-11 PL PL373577A patent/PL211300B1/pl not_active IP Right Cessation
- 2003-04-11 CA CA2482041A patent/CA2482041C/en not_active Expired - Fee Related
- 2003-04-11 RU RU2004133325/04A patent/RU2308454C9/ru not_active IP Right Cessation
- 2003-04-11 JP JP2003585656A patent/JP4664597B2/ja not_active Expired - Fee Related
- 2003-04-11 BR BR0309278-0A patent/BR0309278A/pt not_active Application Discontinuation
- 2003-04-11 AT AT03728389T patent/ATE471931T1/de not_active IP Right Cessation
- 2003-04-11 DE DE60333094T patent/DE60333094D1/de not_active Expired - Lifetime
- 2003-04-11 EP EP03728389A patent/EP1511734B1/en not_active Expired - Lifetime
- 2003-04-11 AU AU2003234733A patent/AU2003234733B2/en not_active Ceased
- 2003-04-11 US US10/412,712 patent/US6924376B2/en not_active Expired - Lifetime
- 2003-04-15 TW TW092108728A patent/TWI282337B/zh not_active IP Right Cessation
- 2003-04-15 AR ARP030101317A patent/AR039419A1/es unknown
- 2003-04-16 MY MYPI20031432A patent/MY140169A/en unknown
-
2004
- 2004-10-14 IL IL164581A patent/IL164581A/en active IP Right Grant
- 2004-10-28 NO NO20044662A patent/NO330433B1/no not_active IP Right Cessation
-
2005
- 2005-06-15 US US11/154,989 patent/US7491746B2/en not_active Expired - Fee Related
-
2008
- 2008-01-22 IL IL188954A patent/IL188954A/en active IP Right Grant
- 2008-06-19 US US12/142,621 patent/US7629477B2/en not_active Expired - Fee Related
-
2009
- 2009-10-20 US US12/582,424 patent/US7919524B2/en not_active Expired - Fee Related
-
2011
- 2011-03-29 US US13/075,076 patent/US8119678B2/en not_active Expired - Fee Related
-
2012
- 2012-01-13 US US13/349,795 patent/US8329928B2/en not_active Expired - Fee Related
- 2012-09-12 US US13/612,686 patent/US8633236B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005523312A5 (https=) | ||
| RU2004133325A (ru) | Соединения, композиции на их основе и способы их использования | |
| JP2006515886A5 (https=) | ||
| CN100491358C (zh) | 嘧啶酮类化合物、组合物及方法 | |
| CA2413426A1 (en) | Methods and compositions utilizing quinazolinones | |
| CA2052884C (en) | Angiotensin 11 antagonists in the treatment of hyperuricemia | |
| RU2394826C2 (ru) | Дизамещенные пиразолобензодиазепины, используемые в качестве ингибиторов cdk2 и ангиогенеза, а также для лечения злокачественных новообразований молочной железы, толстого кишечника, легкого и предстательной железы | |
| AU2004289539C1 (en) | Aryl imidazoles and their use as anti-cancer agents | |
| KR20230011908A (ko) | 비정상적 세포 성장을 치료하기 위한 조합 요법 | |
| Abd El-Meguid et al. | Novel benzimidazole derivatives as anti-cervical cancer agents of potential multi-targeting kinase inhibitory activity | |
| JP2014503534A5 (https=) | ||
| RU2000121556A (ru) | Новые трициклические производные (варианты), фармацевтическая композиция (варианты), способ подавления иммуной реакции или лечения и /или предупреждения аллергических заболеваний (варианты) | |
| HK1251227A1 (en) | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders | |
| US20210078938A1 (en) | Pcna inhibitors | |
| JP2014515401A5 (https=) | ||
| RU98107643A (ru) | Применение замещенных пиразолил бензолсульфонамидов в ветеринарии | |
| JP2006508030A5 (https=) | ||
| JP2006503048A5 (https=) | ||
| CN102665700A (zh) | 治疗实体瘤和其它恶性肿瘤的方法和组合物 | |
| JP2006512293A5 (https=) | ||
| RU2005109912A (ru) | Соединения фенил-индола для модуляции ige и подавления разрастания клеток | |
| WO2009143290A2 (en) | Inducing cell death by inhibiting adaptive heat shock response | |
| US20040186104A1 (en) | Novel pyridinone and related heterocyclic derivatives | |
| US20090099191A1 (en) | Inhibition of nf-kb | |
| RU2005114491A (ru) | Соединения, составы и способы их использования |